aprepitant and pimozide: what the product label says

The product label for aprepitant names pimozide in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.

Which products this evidence covers

CINVANTI — INJECTION, EMULSION — INTRAVENOUS

Labeled active ingredients: APREPITANT. Routes: INTRAVENOUS. Dosage forms: INJECTION, EMULSION.

Supporting label passage

Section: 5.1 Clinically Significant CYP3A4 Drug Interactions

Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of CINVANTI with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug. Use of pimozide with CINVANTI is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide [see Contraindications (4) ] . Use of CINVANTI with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to CINVANTI. Use of CINVANTI with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of CINVANTI. See Table 8 and Table 9 for a listing of potentially significant drug interactions [see Drug Interactions (7.1 , 7.2) ].

Read the full product label on DailyMed. Label version 15, dated 2026-04-01.

Limits of this evidence

This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDI’s severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.

How this brief was prepared

Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-07. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.

Discuss your exact medicines with your pharmacist

Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.

Check your medication list with CDI.